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1. Introduction
Autologous or allogeneic hematopoietic stem cell (HSC)
transplantation has been used successfully in the treatment
of hematological diseases, neoplasias, primary immunode-
ficiency diseases, and metabolic disorders of children and
adult patients. Historically, the bone marrow (BM) has
represented the main source of HSCs in pediatric and adult
individuals. However, in many cases, a suitable donor is
hardly found, thus limiting the applicability of this life-
saving treatment. This difficulty has led to a search for
alternative sources of HSCs for use in human transplanta-
tions. Two sources of human HSCs have been identified:
cord blood (CB) and peripheral blood (PB). PB is consid-
ered to be practical sources of HSCs, especially because
methods exist which can mobilize significant numbers of
stem/progenitor cells into circulation after administration of
G-CSF. However, the poor mobilization happens some-
times, and more importantly, concerns about donor safety
have been apprehended because of splenic rupture during G-
CSF application [1]. HSCs derived from CB have many
advantages for transplantation, but the recipient is restricted
to pediatric patients because of its small volume. These
inconveniences have been considered to be resolved if ex
vivo expansion of HSCs would turn out to reality.
Recently, the identification, cloning, and production of
recombinant cytokines together with the identification and
purification of HSCs and progenitor cells have greatly
increased our understanding of the hematopoietic system.
As a result of these fundamental discoveries, many inves-
tigators are now attempting ex vivo manipulation of HSCs
for potential therapeutic purposes. In general, the objectives
of these manipulations are to expand HSCs responsible for
long-term hematopoietic repopulation. This review will
summarize the present understandings of the roles of cyto-
kines for expansion of human HSCs, together with the
development of assay systems to reflect human HSC activ-
ity correctly. Moreover, therapeutic applications for ex vivo
expanded HSCs will also be discussed [2–4].
2. In vitro and in vivo assessments of human
hematopoietic stem/progenitor activity
2.1. In vitro assays
These assays include long-term culture-initiating cell
(LTCIC) assay, cobblestone area-forming cell (CAFC)
assay, high proliferative potential colony-forming cell
(HPP-CFC) assay, and colony-forming unit-blast (CFU-Bl)
assay [5,6]. However, even with the extended long-term
culture-initiating cell system (ELC-IC) which can detect an
immature progenitor population, it turned out to be impos-
sible to reflect human long-term repopulating stem cells [7].
At present, the available in vitro assays do not appear to
reflect a true measure of human HSC.
2.2. In vivo assay
In order to enhance the study of human HSC, investi-
gators have directed their attention to the development of
small animal models of human hematopoiesis [8]. In mouse,
quantitative competitive repopulating assay between pheno-
typically distinguishable stem cell populations has been
developed as a definitive stem cell assay system [9]. In this
system, mixtures of BM cells from different donors are
injected into irradiated recipient mice, and the relative
portion of each donor-origin population is determined as a
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ratio. This ratio represents the relative HSC content of each
inoculum. The advantages of animal models, particularly
small animal models, are obvious. The development, differ-
entiation, and long-term repopulating capacity of human
cells, which can only be determined in vivo, can be
ascertained in a small animal model without the need for
clinical studies. In 1988, the first report of the engraftment
of human cells into homozygous severe combined immu-
nodeficiency (SCID) mice was presented. This report
included engraftment of human PB mononuclear cells
following intraperitoneal injection into unirradiated recipi-
ents and transplantation of fetal BM and thymus fragments
under the renal capsule. These initial model systems were
soon followed by the experiment of human BM engraftment
when transferred intravenously into irradiated SCID recip-
ients [10].
Recent advances in mammalian genetics have provided a
number of immunodeficient murine models for engraftment
and quantitation of human stem cells. One model is mice
which are triply homozygous for the beige (Lystbg, bg), nu,
and X-linked immunodeficiency (Btkxid, xid) loci (bg-nu-
xid) [11,12]. Additional immunodeficient models include
mice deficient in the recombination activating gene-1
(Rag1) and Rag2 genes and mice homozygous for Prkdcscid
(scid) locus [13–15]. During extensive attempts being made
to utilize the bg-nu-xid mouse, the Rag1 and Rag2-deficient
mice, and the scid mice as hosts for normal and malignant
human hematopoietic cells, the optimal host has been
determined to be mice homoxygous for the scid mutations.
Therefore, small animal models of human HSC engraftment
have been attempted mainly based on the use of the scid
mice (Table 1).
The term SCID-repopulating cell (SRC) has been utilized
to describe the reconstitution activity of the human HSCs
engrafted in SCID. However, the serious limitation has still
precluded the widespread use of SCID mice for detecting
human HSC activity. The engraftment levels of human cells
are low, representing only 0.5–5% of the total SCID
recipient BM population. Systemic approach has been based
on the hypothesis that the poor engraftment level of human
xenograft cells might be derived from the residual innate
immune resistance in host. To evaluate the influence of the
residual innate immunity on the engraftment efficiency, an
extensive screen of SCID mice backcrossed with mice
harboring several impaired innate immunities was eval-
uated. As a result, the NOD/LtSz-scid mouse strain was
generated as an efficient recipient to reconstitute human
hematopoietic cells [16]. This strain has a variety of
immunological abnormalities such as T- and B-cell defi-
ciency, impaired natural killer (NK) cell activity, macro-
phage dysfunction, and absence of circulating complements.
Recently, we also established a similar NOD/Shi-scid mice,
which showed a similar phenotype with NOD/LtSz-scid
[17,18]. These mice injected intravenously with human
CB CD34+ cells were able to support 5- to 10-fold higher
levels of human cell engraftment in their BM than in SCID
mice. However, careful examinations of NOD/LtSz-scid
mice and NOD/Shi-scid mice revealed that both mice still
preserve a subtle NK activity [19]. NK cell depletion by
anti-asialo GM1 antiserum treatment was indispensable in
the enhancement of human HSC engraftment in irradiated
NOD/Shi-scid mice.
To eliminate NK cell activity completely, genetic
crosses produced NOD/LtSz mice doubly homozygous
for scid mutation and the h2 microglobulin null allele
(NOD/LtSz-scid-h2m /) [20]. NOD/LtSz-scid-h2m /
mice resulted in the absence of MHC class I expression,
loss of NK cell activity, and rapid clearance of human
IgG1 in addition to the lacking of mouse mature lympho-
cytes and serum Ig. According to Kollet’s experiments,
NOD/LtSz-scid-h2m / mice are highly efficient recipi-
ents for human HSCs, compared with NOD/LtSz-scid mice
[21].
NOD/LtSz-scid mice are highly radiosensitive, have
short life spans, and a small number develop functional
lymphocytes with age. To overcome these limitations,
Shultz et al. have backcrossed the null allele of the Rag1
gene onto the NOD/LtSz-scid strain background (NOD/
LtSz-Rag1null). Although PB mononuclear cell transplanta-
tion has been performed, there were no significant differ-
ences in the percentage of CD4 or CD8 cells in PB of
engrafted NOD/LtSz-Rag1null compared with the PB of
engrafted NOD/LtSz-scid mice [21]. Now, the engraftment
level of human HSCs into this mouse remains to be
examined.
In either strain of ontogenetically or genetically modified
mice with compromised immunological activity, complete
multilineage differentiation including T cells has not been
Table 1
Immunocompromised mice for evaluating human hematopoietic stem cell activity
T cell B cell NK cell Macrophage Complement Engraftment of
human HSC
Human T cell
SCID | | impossible –
bg-nu-xid | | # impossible –
NOD/LtSz-scid | | # | | possible –
NOD/Shi-scid | | # | | possible –
NOD/LtSz-Rag1 null | | # | | possible –
NOD/LtSz-scid /B2m null | | – | | good –
SCID (Prkdc scid); bg-nu-xid (beige, nude, X-linked immunodeficiency); HSC (hematopoietic stem cell).
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reported. Stem cells are defined functionally by the self-
renewal and multilineage differentiation. To fulfill these
two, complete multilineage differentiation including T cells
is required to be demonstrated. Further improvement
remains to be performed.
3. Effects of cytokines on human hematopoietic stem/
progenitor cells
The optimal choice of cytokines for the ex vivo expan-
sion of human hematopoietic stem/progenitor cells has not
yet been determined. During the last two decades, inves-
tigators in a number of laboratories used murine trans-
plantation models to characterize the cytokines regulating
the human HSCs (Table 2). The positive cytokines may be
separated in to two groups: one consisting of stem cell factor
(SCF) and flt3/flt2 ligand (FL), and the other consisting of
interleukin (IL)-6, IL-11, IL-12, leukemia inhibitory factor
(LIF), granulocyte colony-stimulating factor (G-CSF), and
thrombopoietin (TPO). Interactions of two cytokines appear
necessary to positively regulate the kinetics of stem cells.
Surprisingly, IL-3 and IL-1 proved to have profound neg-
ative effects on HSCs [22]. In spite of these numerous
studies, the definitively continuous expansion of human
HSC in ex vivo system has not been achieved yet, resulting
in no definitive presentation of efficient engraftment
through the ex vivo manipulation procedure. In this review,
we are going to follow these progresses historically. There-
fore, some contradictions among the presented data might
be noticed. Because, earlier studies employed the in vitro
assays (LTC-IC, CFAC, CD34+/CD38 cells) as the meth-
ods for quantitation of human HSCs instead of xenotrans-
plantation assay using NOD/SCID mouse, wrong functions
may be ascribed to specific cytokines unless highly enriched
target cells are used and serum-free conditions are
employed, in order to eliminate any colony-stimulating
activity produced by accessory cells or contained in serum
[23]. For example, the contribution of IL-3 for maintenance
or expansion of human HSCs has continued to be indefinite
until recently.
4. SCF
Mice with mutations at either the dominant W or Sl loci
encoding for the c-kit and SCF, respectively, display a
similar phenotype characterized by a reduction in the
number of HSCs with hypoplastic anemia. Although the
number of molecules per cell varies extensively according to
the cell type, c-kit is now known to be expressed by most of
the hematopoietic cells [24]. SCF plays a central role in the
regulation of early hematopoiesis. In one series of experi-
ments, SCF alone had no effect on HPP-CFCs from CD34+/
HLADR/CD15 human BM cells. However, the addition
of SCF to a combination of IL-3 and granulocyte-macro-
phage colony stimulating factor (GM-CSF) resulted in a 12-
fold increase in the number of HPP-CFC-derived colonies.
Moreover, SCF addition resulted in an increase in the
number of erythroid elements in these colonies. Similar
effects were observed on burst-forming unit-erythroid
(BFU-E), conoly-forming unit granulocyte-macrophage
(CFU-GM), and burst- and colony-forming unit-megakar-
yocyte (BFU-MK and CFU-MK) [25,26]. SCF has been
studied extensively in ex vivo expansion experiments both
in stroma-free and stroma-containing cultures. Although it is
difficult to draw conclusions on the role of any single
cytokine, SCF was frequently represented in the most
effective combinations.
5. FL
On its own, FL has minimal activity in agar cultures of
murine or human BM or CB enriched CD34+ cells, stim-
ulating only dispersed CFU-GM but not HPP-CFC colonies,
Table 2
Ex vivo generation of primitive hematopoietic progenitor/stem cells from human CD34+ cells
CD34+ source Cytokines Test Fold increase Reference
BM SCF, PIXY321 HPP-CFC 5.5 Blood 81:661,1992
PB SCF, IL-1, IL-3, IL-6, EPO LTCIC 1.1 Blood 84:2898,1994
PB IL-1, IL-3, IL-6, SCF, EPO LTCIC > 1 Blood 84:2829, 1994
CB IL-1, IL-3, SCF LTCIC 15–20 Blood Cells 20:468,1994
BM, CB FL, IL-3, IL-6, SCF LTCIC increase Blood 87:3563,1996
BM FL, SCF, IL-3 LTCIC 30 J. Exp. Med. 183:2551,1996
CB SCF, IL-3, IL-6, FL, TPO LTCIC 0–6 Blood 90:365a,1997
CB FL, TPO LTCIC >200,000 Blood 89:2644,1997
BM SCF, IL-3, FL, IL-6, G-CSF, NGF LTCIC 47–68 Proc. Natl. Acad. Sci. U. S. A. 93:1470,1997
CB SCF, FL, IL-6/sIL-6R CFU-Mix increase Blood 90:4363,1997
CB FL, TPO, SCF, IL-6 LTCIC 280 Blood 93:3736,1999
CB SCF, FL, TPO, G-CSF LTCIC 47 Exp. Hematol. 28:1470,2000
CB SCF, FL, TPO, G-CSF E-LTCIC 21 Exp. Hematol. 28:1470,2000
CB SCF, FL, TPO, IL-6/sIL-6R CFU-Mix increase J. Clin. Invest. 105:1013,2000
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mixed colony-forming unit (CFU-Mix), or BFU-E. How-
ever, in combination with other cytokines, such as SCF, IL-
3, and GM-CSF, FL has addictive or more than addictive
effects. These effects remain apparent even on single cells in
wells [27]. Several lines of evidence suggest that FL works
on the early myeloid progenitors. First, FL receptors are
only detectable on CD34+ but not CD34 human BM cells
[28]. Second, in suspension cultures of CD34+ column-
separated CB cells, whereas SCF and GM-CSF/IL-3 fusion
protein (PIXY321) favor the expansion of the more imma-
ture progenitors, the addition of FL enhances the amplifi-
cation of more immature progenitors [27]. Third, FL was the
only cytokine to increase the number of LTC-ICs above the
input value after 10 days of liquid cultures of CD34+/
CD38 human BM cells [29]. Fourth, serum levels of FL,
but not SCF, are elevated in patients with multilineage BM
failure and correlate inversely with the colony-forming
abilities of BM progenitors from these patients. The levels
do not normalize after correction of a single lineage, such as
after the transfusion of red blood cells [30].
In ex vivo expansion experiments, FL was compared to
SCF. Neither factor could alone support the proliferation of
Lin/Sca-1+/c-kit+ cells derived from 5-FU-treated murine
BM cells in suspension cultures. Both factors were, how-
ever, synergistic with IL-11, enhancing the production of
progenitors and of nucleated cells. Longer exposure to FL
was required. No engraftment defect after incubation with
these cytokines was noted after transplantation into lethally
radiated mice except for the cells exposed to SCF and IL-11
for 21 days [31]. In a different set of experiments, FL in
combination with TPO resulted in extensive expansion with
little differentiation of CD34+ CB cells cultured under
stroma-free conditions. In stroma-free cultures of human
CD34+ CB cells, FL in combination with TPO induced a
several-thousandfold expansion of both CD34+/CD38 and
CD34+/CD38+ populations after 20 weeks of culture. Fur-
thermore, when the expanded cells were stimulated by IL-7,
IL-11, and FL, the percentage of CD2+ and CD19+ cells
reached 33.8% and 3.7%, respectively, after 14 days,
suggesting that T- and B-lymphocyte progenitors were also
expanded.
6. TPO
TPO has been shown in several studies to play a pivotal
role in the regulation of megakaryopoiesis. In vitro, TPO
promotes the proliferation and differentiation of immature
megakaryocytes [32]. Its augmenting effects on CFU-MK
are synergistic when combined with IL-3 and IL-6 [33].
Compared to those generated in cultures containing IL-3,
megakaryocytes produced in the presence of TPO showed
increased ploidy. TPO is lineage predominant but not
specific [34]. Besides governing platelet production, TPO
has a noticeable effect on the myeloid and erythroid line-
ages. When single adult BM CD34+/Thy1+/Lin cells were
cultured in the presence of a murine stromal cell line, TPO
alone resulted in a plating efficiency of 63% with an average
of 531 cells per 1 cell input [35]. Although some culture
displayed megakaryocytic differentiation, about 75% of
cultures exhibited blast cell outgrowths with myeloid, eryth-
roid, and megakaryocytic potential, suggesting that a hier-
archy exists among CD34+/Lin/Thy1+ cells and that the
least mature cells can be expanded under the influence of
TPO while maintaining a multilineage differentiation poten-
tial. Similarly, TPO acted synergistically with SCF and IL-3
to support the production of CFU-GM, CFU-E, and CFU-
Mix in suspension cultures of CD34+/c-kitlow/CD38low
human BM cells [36].
7. IL-6/sIL-6R
IL-6 is a member of the IL-6 cytokine family, which also
includes IL-11, ciliary neurotrophic factor (CNTF), leuke-
mia inhibitory factor (LIF), oncostatin M (OSM), and
cardiotropin-1 (CT-1) [37]. These cytokines mediate their
biologic action through the common subunit gp130. Bind-
ing of IL-6 to IL-6 receptor (IL-6R) induces homodimera-
rization of gp130, which in turn leads to intracellular
signaling events. The gp130 molecule has been shown to
play an important role in hematopoiesis, as gp130-deficient
mice exhibit a greatly diminished number of hematopoietic
progenitors [38]. IL-6 alone does not have distinct bio-
logical activity on HSC expansion. IL-6 has been shown to
act as a potent cofactor in the expansion of human CD34+
progenitor cells in vitro [39–41]. IL-6 and IL-3 induce
synergistically the proliferation of murine pluripotent hem-
atopoietic progenitors in vitro [42]. The combination of IL-6
and IL-3 acts on blast cell colony forming cells to cause
them to leave G0 earlier. However, we and others demon-
strated that pluripotent HSC express only low levels of Flk2/
Flt3 and c-kit while lacking expression of IL-6R [43–45].
Activation of gp130 signaling in cells lacking IL-6R can be
achieved through a complex of IL-6 and soluble IL-6R (IL-
6/sIL-6R) [46,47]. We will mention later again, direct
stimulation of gp130 by IL-6/sIL-6 in the presence of SCF
has been shown to induce extensive proliferation of human
hematopoietic progenitor cells in vitro [47]. In this system,
the high concentration of sIL-6R protein is required. Using a
novel approach, a fusion protein consisting of IL-6 and sIL-
6R linked by a flexible polypeptide (Hyper-IL-6) was
produced and has been shown to be useful at 100- to
1000-fold lower concentrations than unlinked IL-6 and
sIL-6R [48]. The combination of Hyper-IL-6 and FL was
markedly effective for expansion of PB CD34+ cells [49].
8. IL-3
IL-3 has the broadest target specificity of any of the
cytokines and the hematopoietic growth factors. The range
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of target cells can be summarized as including progenitor
cells of every lineage derived from the pluripotent HSCs.
Moreover, IL-3 acts on more immature hematopoietic cells.
The contribution of IL-3 for the self-renewal of HSCs varies
from report to report. IL-3 stimulates the growth in vitro of
colonies containing mixtures of myeloid and erythroid cells
and stimulates both in vitro and in vivo the division of cells
(CFUs) that form splenic colonies in irradiated mice [50].
IL-3 also stimulates the growth of human HSCs with
significant capacity for self-renewal [51]. However, accord-
ing to Peters’ report, stimulation with IL-3 may results in a
decreased ability of stem cell populations to self-renew as
assessed by long-term repopulating capacity [3,52]. We also
demonstrated that addition of IL-3 to the cytokine combi-
nation of SCF, FL, TPO, and IL-6/sIL-6R abrogated the
repopulating ability of the expanded CB CD34+ cells [17].
9. Combination of cytokines for the expansion of human
hematopoietic stem/progenitor cells
The optimal choice of hematopoietic growth factors for
the ex vivo expansion of human HSCs has not yet been
determined. Various combinations of cytokines were exam-
ined. One of the most important cytokines is SCF, which was
shown to be a survival factor for hematopoietic progenitor
cells even in the absence of cell division [53]. Various other
cytokines, including IL-1, IL-3, IL-6, G-CSF, GM-CSF, and
erythropoietin (EPO), also have been investigated with
respect to their ability to expand hematopoietic stem/progen-
itor cells. Recently, two cytokines (FL and TPO) have been
shown to significantly improve the generation of stem/pro-
genitor cells ex vivo. FL strongly potentiates the clonogenic
capacity of immature progenitor/stem cells when combined
with other growth factors [31,41,54–57]. TPO, in addition to
its effects on the megakaryocytic cell lineage, enhances
proliferation of stem/progenitor cells [32,58,59]. The repre-
sentative combinations of cytokines attempted are listed in
Table 2. The addition of growth factors (e.g., G-CSF, GM-
CSF, and EPO) to these cytokines results in optimal gener-
ation of committed progenitor cells.
Recently, we have shown that gp130 is expressed at a
low level of most CD34+ cells isolated from human CB,
whereas IL-6R is expressed in only 30% to 50% of these
cells [47]. The complex of IL-6 and sIL-6R can stimulate
the cells which express only gp130 without IL-6R. Clonal
cultures of fluorescence-activated cell-sorted CD34+IL-6R+
and CD34+IL-6R cells revealed that most immature pro-
genitors such as multipotent colony-forming units (granu-
locyte-erythrocyte-macrophage-megakaryocyte colony-
forming units [CFU-GEMM] and blast colony-forming
units (CFU-Blast)] were included in CD34+IL-6R cells
in methylcellulose culture with a combination of IL-6, sIL-
6R, and SCF 45. In a serum-free suspension of CD34+IL-
6R cells in culture supplemented with a combination of IL-
6, sIL-6R, FL, and TPO in the presence or absence of SCF,
the number of multipotent immature progenitor/stem cells
dramatically increased.
We are not sure whether this procedure is also effective
for the expansion of progenitor/stem cells derived from BM
or PB. Several authors described that the growth factor
requirement for the expansion of HSC from different
sources is not equivalent. Based on these viewpoints, the
optimal combination of cytokines for HSC expansion is
required to be evaluated individually.
10. In vivo evaluation of expanded HSCs using NOD/
SCID mice
The most challenging question in stem-cell biology is
whether the most immature progenitor/stem cells also can be
expanded ex vivo. The most reliable method for quantitation
of these cells is in vivo assays using xenotransplantation into
NOD/SCID mice (SCID-repopulating cell, SRC) [60,61]. To
verify whether ex vivo-cultured human CD34+ cell popula-
tions might lose or increase true stem-cell properties com-
pared with freshly isolated CD34+ cells, several in vivo
models have been investigated. Table 3 reveals the represen-
tative experiments for human hematopoietic cells. We dem-
onstrated that the dramatic amplification of human HSCs
capable of repopulating in NOD/SCID mice can be obtained
in culture system of CB CD34+ cells with SCF, FL, TPO, and
IL-6/sIL-6R. The contribution of sIL-6R is indispensable to
this efficient expansion. Interestingly, Peters et al. reported
that expansion of murine hematopoietic progenitor/stem cell
cultures with SCF, IL-3, IL-6, and IL-11 led to an engraftment
defect of long-term repopulating cells, although short-term
reconstitution capability was maintained [3]. Similar obser-
vations have been described by Yonemura et al. [52], indicat-
ing that the addition of IL-1 and IL-3 for ex vivo expansion of
primitive hematopoietic cells significantly reduces reconsti-
Table 3
In vivo studies with ex vivo-expanded hematopoietic stem/progenitor cells
CD34+ source Cytokines used for expansion Long-term reconstitution References
CB FL, SCF, IL-3, IL-6, G-CSF two fold increase in SRC Proc. Natl. Acad. Sci. 94:9836,1997
CB FL, SCF, IL-3, IL-6, G-CSF two- to four fold increase in SRC J. Exp. Med. 186:619,1997
CB FL, SCF, TPO, IL-6 increase Blood 93:3736,1999
CB FL, SCF, TPO, IL-6/sIL-6R 4.2-fold increase in SRC J. Clin. Invest. 105:1013,2000
CB FL, SCF, TPO, IL-3, IL-6, IL-11 increase Br. J. Haematol. 108:629,2000
CB FL, SCF, TPO, G-CSF increase Exp. Hematol. 28:1470,2000
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tution ability compared with cells stimulated without these
two factors.
We also observed that the addition of IL-3 to efficient
amplification system with SCF, FL, TPO, and IL-6/sIL-6R
abrogates the repopulating ability of the expanded cells [17].
However, in contrast, other reports have shown that ex vivo
expansion with hematopoietic growth factors—excluding
high-dose IL-1 and IL-3—allows for both short- and long-
term reconstitution, as well as the ability to transplant these
cells serially [62,63]. Based on these data, the use of IL-1
and/or IL-3 has to be evaluated carefully in attempts to
expand primitive HSC ex vivo for use in a myeloablative
clinical setting.
11. Clinical experience with ex vivo-generated stem/
progenitor cells
HSC transplantation has undergone a dramatic change
over the past few years both in the number of transplants and
in the way that these transplants are being done. There are a
variety of clinical applications for culture and/or expansion
of immature hematopoietic progenitor/stem cells [64,65].
These include increasing the number of stem cell trans-
plantation cases where a therapeutic dose of transplantable
cells cannot be obtained by conventional methods. The first
report on the use of ex-vivo-manipulated stem cells to
transplant patients came from Brugger et al. [66] and was
designed to test the safety of ex vivo manipulation of stem
cells. PB progenitor cells were harvested from 10 G-CSF
mobilized patients with a variety of solid tumors (lung
carcinoma, breast cancer, sarcoma, or undefined tumor)
following nonablative chemotherapy. An average of
1107 CD34+ immature hematopoietic cells were cultured
for 12 days in media containing autologous plasma, SCF, IL-
1h, IL-3, IL-6, and EPO. Each patient received ex vivo-
expanded PB progenitor cells following two cycles of
induction therapy. Four of the patients also received unma-
nipulated BM cells to supplement the cultured cells. All of
them gained an absolute neutrophil count of >500/mm3 by
day 12 along after receiving a dose of >100,000 CFU-GM/kg
body weight. Platelet count also CFU-recovered to >20,000/
mm3 by day 12 and reached to >50,000/mm3 by day 14.
Analyses of the correlation between the time to hemato-
poietic recovery and the number of transplanted colony-
forming cells suggested that a threshold dose of approxi-
mately 105 CFU-GM/kg was needed for rapid engraftment.
Although immature hematopoietic progenitor cells, as
defined by LTC-IC, persist under the culture conditions
used, the capability of the ex vivo-generated cells for long-
term hematopoiesis cannot be determined by this study.
In another clinical study, Alcorn et al. [67] reinfused into
patients ex vivo-expanded cells along with unmanipulated
cryopreserved PB progenitor cells. The protocol was safe,
and hematopoietic recovery was not influenced by the
additional transplantation of ex vivo-generated cells.
Recently, these investigators reported on four additional
patients who received ex vivo-expanded cells only after
truly myeloablative chemotherapy [68]. Short-term hema-
topoietic recovery of neutrophils was observed in three of
the four patients. The patient who did not engraft by day 14
had received the lowest dose of CFU-GM. However, at least
two of the three patients with short-term reconstitution
failed to show long-term engraftment after myeloablative
conditioning. These observations indicate that a procedure
which allows expansion of committed progenitors but no
expansion of more immature hematopoietic cells in fact may
not contain sufficient numbers of long-term repopulating
stem cells to insure persistent engraftment after myeloabla-
tive therapy.
A subsequent report addressed the ability of ex vivo-
cultured stem cells to provide durable engraftment in a
myeloablative host. Breast cancer patients undergoing
high-dose chemotherapy had BM cells harvested for expan-
sion in a perfusion bioreactor just prior to therapy. Cells
were used to seed the bioreactor where cultures were grown
for 12 days in EPO, PIXY321, and FL. The use of a
mononuclear cell population in this bioreactor system was
shown to be superior to inoculating with purified CD34+/
Lin cells presumably due to the presence of stroma cells in
the inoculum [69]. Under these conditions, CFU-GM was
expanded 10-fold but LTCIC and CD34+/Lin cells were
reduced to half or less of the input amount. Still, all patients
showed rapid neutrophil and platelet engraftment (an aver-
age of 18 and 23 days) that was sustained for several months
of follow-up.
Recently, Stiff et al. [70] reported that the ex vivo
expansion of small numbers of BM cells, without prior
CD34+ cell selection, in a stroma-based bioreactor with
exogenous PIXY-321, FL, and EPO support was able to
produce durable hematopoietic reconstitution after myeloa-
blative chemotherapy in 16 patients with advanced breast
cancer. McNiece also reported the ex vivo-expanded PB
progenitor cells as a source of hematopoietic support to
decrease or eliminate the period of neutropenia, with long-
term engraftment. CD34+ cells selected from G-CSF mobi-
lized PB progenitor cells from patients with breast cancer
were cultured for 10 days in defined medium containing SCF,
G-CSF and TPO [71]. The patients who received expanded
PB progenitor cells engrafted neutrophils in a median of 8
days. These patients are past the 15-month posttransplanta-
tion stage with no evidence of late graft failure.
Several abstracts were reported at the American Society
of Hematology meeting in Miami describing studies of ex
vivo expansion using the Aastrom cell production system
for CB and PBPC. Kurtzberg and colleagues described the
expansion of CB products that were transplanted into 21
patients. Each patient received unmanipulated CB cells on
day 0 and the expanded cells on day + 12. No significant
effects on engraftment kinetics were observed in these
patients. Stiff and colleagues also reported on expansion
of CB cells in the Aastrom system for nine patients. The
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median time to neutrophil engraftment was 26 days, with a
range of 14 to 36 days. Engraftment of platelets was delayed
in these patients. The authors conclude that ex vivo-
expanded CB cells may be useful in adults with otherwise
incurable hematologic disorders. The Aastrom system has
also been used for the expansion of BM cells. Studies have
demonstrated that expansion of a small aliquot of BM cells
can provide short- and long-term engraftment following
myeloablative chemotherapy [72]. Other studies have com-
bined the expanded BM cells with single PB progenitor cell
products, and in the reports the patients engraft neutrophils
and platelets equivalent to optimal PB progenitor cell
products. The evaluation of these reports is required to be
properly done.
12. Future prospect
A great deal of experiences over the past 10 years in terms
of the ability to isolate and culture primitive hematopoietic
stem and progenitor cells has been attempted. However,
nobody has yet reached a stage to use ex vivo-expanded cells
routinely for hematopoietic replacement therapy [65]. Issues
related to the identification of human HSC still remain to be
dissolved to characterize the expanded population that keeps
durable hematopoietic reconstitution. The advantage of ani-
mal models of transplantation has allowed us to create
reliable criteria for evaluating the stem cell content of a
population. However, these models require several months
to provide an answer. Growth factors and other soluble
factors of stem cell proliferation have provided great insight
into the biology of stem cells, but we do not yet understand
how to organize these molecules in a physiologically relevant
manner. Up to now, regrettably, no clinical state has been
identified in which transplantation of expanded cells was
clearly advantageous over unmanipulated cells. Moreover,
successful expansion of HSCs is not to be expected from
heavily pretreated patients. To be widely accepted for clinical
use, procedures for ex vivo stem cell expansion are required
to meet the requirements for Good Manufacturing Practices
(GMPs).
Although many issues to be settled remain now, the
tremendous progress has been in progress in this field. The
perpetual discoveries in molecular biology and developmen-
tal biology help this process cooperatively. The establishment
of the procedure for clinical application of ex vivo-expanded
HSCs should pave the way to the new era for intractable
disorders now and build up hope for these patients.
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